Japanese pharma shifting earlier to CDMOs, report says
Japanese pharma companies are shifting to earlier CDMO outsourcing, Neuland Laboratories has said.
According to the report, pharma companies are engaging contract development and manufacturing organisations (CDMOs) earlier in the development cycle, as increasing complexity in peptide programmes places greater strain on in-house capabilities.
This trend is being driven in part by growing activity from venture-backed biotech companies and spinouts emerging from large pharmaceutical R&D organisations. As these programmes advance into clinical development, demand for specialised CDMO capabilities is increasing.
Neuland has also noted a rise in peptide-related engagements from Japanese companies, particularly at the preclinical and early clinical stages, where technical requirements are more demanding.
Peptide development presents several challenges compared with traditional small molecules. Analytical complexity remains a key issue, with structural characteristics making characterisation, impurity detection and purity assessment more difficult.
Scale-up is also constrained by the availability and quality of protected amino acids, which can affect manufacturing timelines, cost and overall success rates. Elsewhere, regulatory expectations can further add to the burden.
“The bottleneck isn’t discovery anymore, it’s execution,” said Sharadsrikar Kotturi, Chief Scientific Officer at Neuland Laboratories.
“In peptides, programmes are running into challenges around analytical complexity, scale-up and the availability of key raw materials such as protected amino acids.”
